Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Cerus ( (CERS) ).
On March 16, 2026, Cerus Corporation announced that Chief Operating Officer Vivek Jayaraman will become president and chief executive officer effective July 1, 2026, succeeding William “Obi” Greenman, who will transition to executive chairman while Jayaraman also joins the board. The leadership change formalizes a planned succession and elevates a long-serving commercial and operations executive with prior experience at TriVascular and Medtronic.
In connection with the promotion, Cerus detailed a new compensation package for Jayaraman that includes a higher base salary, increased bonus opportunities, and equity awards tied to both time-based vesting and performance criteria. The structure of the equity and severance terms, including accelerated vesting and change-in-control protections, underscores the board’s effort to align executive incentives with shareholder value and provide continuity during potential strategic or corporate events.
The most recent analyst rating on (CERS) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Cerus stock, see the CERS Stock Forecast page.
Spark’s Take on CERS Stock
According to Spark, TipRanks’ AI Analyst, CERS is a Neutral.
The score is driven primarily by improving fundamentals (revenue growth, reduced losses, better leverage, and recently positive cash generation) and a constructive earnings outlook with reaffirmed 2026 growth and continued positive adjusted EBITDA. Offsetting factors are the lack of consistent GAAP profitability, margin and reimbursement-related uncertainties highlighted on the call, and only neutral technical momentum with the stock below key short-term moving averages.
To see Spark’s full report on CERS stock, click here.
More about Cerus
Cerus Corporation operates in the medical technology sector, developing products for blood safety and transfusion medicine. The company focuses on technologies designed to enhance the safety of blood components, positioning it within the broader global medical device and biotech markets that serve hospitals, blood centers, and healthcare systems.
Average Trading Volume: 1,647,909
Technical Sentiment Signal: Sell
Current Market Cap: $324.8M
See more data about CERS stock on TipRanks’ Stock Analysis page.